Safety and efficacy of biologics, and the future direction of rheumatoid arthritis therapy

Eric M. Ruderman

doi:10.2217/ijr.12.49

Safety and efficacy of biologics, and the future direction of rheumatoid arthritis therapy

Eric M. Ruderman^*

^*Corresponding author for this work

Medicine, Rheumatology Division

Research output: Contribution to journal › Review article › peer-review

Abstract

Eric M Ruderman is a professor of medicine at the Northwestern University Feinberg School of Medicine (IL, USA) and the clinical practice director for the division of rheumatology. His clinical interests include the medical management of rheumatoid arthritis and the spondyloarthropathies. In 2001, he established one of the first rheumatology/dermatology cooperative clinics in the USA for the management of of psoriasis and psoriatic arthritis. He has been an investigator in over 50 clinical trials studying both biologic and nonbiologic therapies for rheumatic diseases. In line with his ongoing interest in patient safety, he has served on the data safety monitoring boards for a number of NIH and industry-sponsored clinical trials, and he currently serves as vice-chair for Northwestern Universitys Institutional Review Board.

Original language	English (US)
Pages (from-to)	473-474
Number of pages	2
Journal	International Journal of Clinical Rheumatology
Volume	7
Issue number	5
DOIs	https://doi.org/10.2217/ijr.12.49
State	Published - Oct 1 2012

ASJC Scopus subject areas

Rheumatology

Access to Document

10.2217/ijr.12.49

Fingerprint Dive into the research topics of 'Safety and efficacy of biologics, and the future direction of rheumatoid arthritis therapy'. Together they form a unique fingerprint.

Cite this

@article{26a1a3a6cab44c1bb448bb913b77ea48,

title = "Safety and efficacy of biologics, and the future direction of rheumatoid arthritis therapy",

abstract = "Eric M Ruderman is a professor of medicine at the Northwestern University Feinberg School of Medicine (IL, USA) and the clinical practice director for the division of rheumatology. His clinical interests include the medical management of rheumatoid arthritis and the spondyloarthropathies. In 2001, he established one of the first rheumatology/dermatology cooperative clinics in the USA for the management of of psoriasis and psoriatic arthritis. He has been an investigator in over 50 clinical trials studying both biologic and nonbiologic therapies for rheumatic diseases. In line with his ongoing interest in patient safety, he has served on the data safety monitoring boards for a number of NIH and industry-sponsored clinical trials, and he currently serves as vice-chair for Northwestern Universitys Institutional Review Board.",

author = "Ruderman, {Eric M.}",

year = "2012",

month = oct,

day = "1",

doi = "10.2217/ijr.12.49",

language = "English (US)",

volume = "7",

pages = "473--474",

journal = "Future Rheumatology",

issn = "1758-4272",

publisher = "Future Medicine Ltd.",

number = "5",

}

TY - JOUR

T1 - Safety and efficacy of biologics, and the future direction of rheumatoid arthritis therapy

AU - Ruderman, Eric M.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Eric M Ruderman is a professor of medicine at the Northwestern University Feinberg School of Medicine (IL, USA) and the clinical practice director for the division of rheumatology. His clinical interests include the medical management of rheumatoid arthritis and the spondyloarthropathies. In 2001, he established one of the first rheumatology/dermatology cooperative clinics in the USA for the management of of psoriasis and psoriatic arthritis. He has been an investigator in over 50 clinical trials studying both biologic and nonbiologic therapies for rheumatic diseases. In line with his ongoing interest in patient safety, he has served on the data safety monitoring boards for a number of NIH and industry-sponsored clinical trials, and he currently serves as vice-chair for Northwestern Universitys Institutional Review Board.

AB - Eric M Ruderman is a professor of medicine at the Northwestern University Feinberg School of Medicine (IL, USA) and the clinical practice director for the division of rheumatology. His clinical interests include the medical management of rheumatoid arthritis and the spondyloarthropathies. In 2001, he established one of the first rheumatology/dermatology cooperative clinics in the USA for the management of of psoriasis and psoriatic arthritis. He has been an investigator in over 50 clinical trials studying both biologic and nonbiologic therapies for rheumatic diseases. In line with his ongoing interest in patient safety, he has served on the data safety monitoring boards for a number of NIH and industry-sponsored clinical trials, and he currently serves as vice-chair for Northwestern Universitys Institutional Review Board.

UR - http://www.scopus.com/inward/record.url?scp=84867558083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867558083&partnerID=8YFLogxK

U2 - 10.2217/ijr.12.49

DO - 10.2217/ijr.12.49

M3 - Review article

AN - SCOPUS:84867558083

VL - 7

SP - 473

EP - 474

JO - Future Rheumatology

JF - Future Rheumatology

SN - 1758-4272

IS - 5

ER -